Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide
Christopher N Bredeson, Mei-Jie Zhang, Manza-A Agovi, Andrea Bacigalupo, Nizar J Bahlis, Karen Ballen, Christopher Brown, M Ahsan Chaudhry, Mary M Horowitz, Seira Kurian, Diana Quinlan, Catherine E Muehlenbien, James A Russell, Lynn Savoie, J Douglas Rizzo, Douglas A Stewart, Christopher N Bredeson, Mei-Jie Zhang, Manza-A Agovi, Andrea Bacigalupo, Nizar J Bahlis, Karen Ballen, Christopher Brown, M Ahsan Chaudhry, Mary M Horowitz, Seira Kurian, Diana Quinlan, Catherine E Muehlenbien, James A Russell, Lynn Savoie, J Douglas Rizzo, Douglas A Stewart
Abstract
We have reported a lower incidence of acute graft-versus-host disease (aGVHD) with a novel conditioning regimen using low-dose rabbit antithymocyte globulin (ATG; Thymoglobulin [TG]) with fludarabine and intravenous busulfan (FluBuTG). To assess further this single-center experience, we performed a retrospective matched-pair analysis comparing outcomes of adult patients transplanted using the FluBuTG conditioning regimen with matched controls from patients reported to the CIBMTR receiving a first allogeneic hematopoietic stem cell transplant (HCT) after standard oral busulfan and cyclophosphamide (BuCy). One hundred twenty cases and 215 matched controls were available for comparison. Patients receiving FluBuTG had significantly less treatment related mortality (TRM; 12% versus 34%, P < .001) and grades II-IV aGVHD (15% versus 34%, P < .001) compared to BuCy patients. The risk of relapse was higher in the FluBuTG patients (42% versus 20%, P < .001). The risks of chronic GVHD (cGVHD) and disease free survival (DFS) were similar in the cases and controls. These results suggest that the novel regimen FluBuTG decreases the risk of aGVHD and TRM after HLA-identical sibling HSCT, but is associated with an increased risk of relapse, resulting in similar DFS. Whether these conditioning regimens may be more suitable for specific patient populations based on relapse risk requires testing in prospective randomized trials.
Source: PubMed